FY2024 EPS Estimate for Alto Neuroscience Lifted by Analyst

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities research analysts at William Blair raised their FY2024 earnings per share estimates for shares of Alto Neuroscience in a research report issued on Wednesday, November 13th. William Blair analyst M. Minter now anticipates that the company will earn ($2.65) per share for the year, up from their previous estimate of ($2.73). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.60) per share. William Blair also issued estimates for Alto Neuroscience’s Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.47) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($2.21) EPS and FY2028 earnings at ($3.06) EPS.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05.

A number of other equities analysts have also recently commented on the stock. RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird reduced their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd. Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Finally, Stifel Nicolaus decreased their price objective on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Alto Neuroscience Stock Performance

ANRO opened at $4.48 on Monday. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a one year low of $3.61 and a one year high of $24.00. The business’s 50-day simple moving average is $9.50 and its 200-day simple moving average is $11.20.

Institutional Trading of Alto Neuroscience

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its position in shares of Alto Neuroscience by 1.4% during the 3rd quarter. FMR LLC now owns 2,363,056 shares of the company’s stock valued at $27,033,000 after acquiring an additional 32,040 shares during the period. RA Capital Management L.P. acquired a new position in Alto Neuroscience during the first quarter worth $21,267,000. Jennison Associates LLC boosted its position in Alto Neuroscience by 80.3% during the third quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after purchasing an additional 370,612 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Alto Neuroscience by 4.8% in the third quarter. Vestal Point Capital LP now owns 650,000 shares of the company’s stock valued at $7,436,000 after buying an additional 30,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Alto Neuroscience in the first quarter valued at $9,788,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.